[Successful Treatment of Gastric Cancer with Conversion Surgery after Nivolumab Treatment-A Case Report].
Gan To Kagaku Ryoho
; 46(10): 1614-1616, 2019 Oct.
Article
en Ja
| MEDLINE
| ID: mdl-31631152
ABSTRACT
Immunocheckpoint inhibitors including anti-PD-1 antibody have shown certain therapeutic effects on various cancer types. They have also attracted great attention as novel cancer treatment options in addition to surgical resection, chemotherapy, and radiation therapy. Herein, we report a case of gastric cancer that was successfully treated with conversion surgery after nivolumab treatment. The patient was 68 years old and male. Upper gastrointestinal endoscopy revealed a type 3 tumor in the antrum, and he was referred to our department for further examination. The gastric cancer was diagnosed as cT4aN2M0, cStage â
¢A, and he was administered SOX as the first-line and nab-PTX/RAM as the second-line treatment, which was also a PD. As the third-line treatment, nivolumab showed remarkable reduction of the tumor after initiation, and after 14 courses, conversion surgery was performed. The patient remains alive without recurrence.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias Gástricas
/
Nivolumab
Límite:
Aged
/
Humans
/
Male
Idioma:
Ja
Revista:
Gan To Kagaku Ryoho
Año:
2019
Tipo del documento:
Article